Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Abstract: In general, the present invention provides methods for promoting the function of retinal cells using neuregulins. A novel aspect of the invention involves the use of neuregulins as growth factors tp promote survival of retinal cells. Treating of the retinal cells to provide these effects may be achieved by contacting retinal cells with a polypeptide described herein. The treatments may be provided to slow or halt net cell loss or to increase the amount or quality of retinal tissue present in the vertebrate.

Abstract: The present invention relates to methods of affecting cellular communication in a vertebrate. The communication is affected by the administration of a neuregulin to a vertebrate, where the neuregulin interacts with a first cell type which results in the production of a product (i.e., Product A). This product, in turn, affects the function of a second cell type. Methods are disclosed in which the affect in function of the second cell type, described above, results in the production of a second product (i.e., Product B) which, in turn, can affect the function of the first cell type or a third cell type. Additional methods are included for treatment of disorders involving an altered or inadequate level of production of a product involved in cellular communication.

Abstract: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.

Abstract: The present invention relates to methods of affecting cellular communication in a vertebrate. The communication is affected by the administration of a neuregulin to a vertebrate, where the neuregulin interacts with a first cell type which results in the production of a product (i.e., Product A). This product, in turn, affects the function of a second cell type. Methods are disclosed in which the affect in function of the second cell type, described above, results in the production of a second product (i.e., Product B) which, in turn, can affect the function of the first cell type or a third cell type. Additional methods are included for treatment of disorders involving an altered or inadequate level of production of a product involved in cellular communication.

Abstract: Novel vectors are disclosed for use in filamentous fungi such as Aspergillus sp. in particular, whereby protein coding regions may be inserted therein to achieve expression or expression followed by secretion of the coded protein from the host. Signal peptide sequences and promoter sequences valuable for this purpose are disclosed as are expression vectors containing coding regions native or foreign to the fungal host. In accordance with the invention, a filamentous fungus such as Aspergillus may be provided with foreign or natural coding regions associated with foreign or natural promoter sequences and optionally signal peptide sequences which can be used to control the expression and/or secretion of the proteins encoded by these coding regions.

Abstract: Novel vectors are disclosed for use in filamentous fungi such as Aspergillus sp. in particular, whereby protein coding regions may be inserted therein to achieve expression or expression followed by secretion of the coded protein from the host. Signal peptide sequences and promoter sequences valuable for this purpose are disclosed as are expression vectors containing coding regions native or foreign to the fungal host. In accordance with the invention, a filamentous fungus such as Aspergillus may be provided with foreign or natural coding regions associated with foreign or natural promoter sequences and optionally signal peptide sequences which can be used to control the expression and/or secretion of the proteins encoded by these coding regions.

Abstract: The invention relates to constitutive promoters useful to control gene expression in Aspergillus hosts. The promoters are derived from the Aspergillus nidulans aldA gene.

Abstract: Transformants of Aspergillus niger and related Aspergilli, containing foreign DNA conferring modified properties of expression thereon, are prepared by use of a DNA vector which contains a selectable marker which is capable of incorporation into the DNA of the host A. niger cells, but which is not to be found in the A. niger cells prior to this transformation. The vector also contains other foreign DNA to be incorporated into the A. niger, for modified expression. The process suitably uses mutants of A. niger as hosts, the mutants lacking the selectable marker as compared with wild type A. niger, and conducts the transformation on spheroplasts of A. niger.